Handelsbanken Fonder AB bought a new stake in Agilent Technologies Inc (NYSE:A) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 72,992 shares of the medical research company’s stock, valued at approximately $4,883,000.
Several other institutional investors have also made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Agilent Technologies by 139.1% in the first quarter. Royal Bank of Canada now owns 404,795 shares of the medical research company’s stock valued at $27,080,000 after acquiring an additional 1,439,500 shares during the period. Robecosam AG lifted its position in Agilent Technologies by 24.0% during the first quarter. Robecosam AG now owns 601,847 shares of the medical research company’s stock worth $40,264,000 after purchasing an additional 116,332 shares during the period. Sandler Capital Management bought a new stake in Agilent Technologies during the first quarter worth about $3,110,000. Verition Fund Management LLC lifted its position in Agilent Technologies by 17.3% during the first quarter. Verition Fund Management LLC now owns 27,746 shares of the medical research company’s stock worth $1,856,000 after purchasing an additional 4,085 shares during the period. Finally, Highland Capital Management LP bought a new stake in Agilent Technologies during the first quarter worth about $1,673,000.
A number of research firms have recently commented on A. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a report on Tuesday, March 27th. Goldman Sachs Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating in a report on Monday, April 9th. Morgan Stanley dropped their target price on shares of Agilent Technologies from $95.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, April 11th. Cowen raised shares of Agilent Technologies from a “market perform” rating to an “outperform” rating in a report on Tuesday, May 15th. Finally, ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $72.75.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, May 14th. The medical research company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.01. Agilent Technologies had a return on equity of 18.01% and a net margin of 5.02%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the prior year, the firm posted $0.58 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. sell-side analysts predict that Agilent Technologies Inc will post 2.67 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 25th. Stockholders of record on Tuesday, July 3rd will be paid a $0.149 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Monday, July 2nd. Agilent Technologies’s dividend payout ratio is currently 25.42%.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 4,000 shares of the stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $67.28, for a total transaction of $269,120.00. Following the completion of the sale, the insider now owns 72,547 shares of the company’s stock, valued at approximately $4,880,962.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Boon Hwee Koh sold 6,931 shares of the stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $66.38, for a total transaction of $460,079.78. The disclosure for this sale can be found here. Insiders sold 15,931 shares of company stock valued at $1,069,650 in the last ninety days.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.